Statements in this presentation and made during today's conference call regarding the timing and magnitude of recovery in the Company's end markets, the continuing impacts of COVID-19 on the Company's results, sales, Adjusted EBIT, Adjusted EBITDA, Adjusted EPS, cash flow, results of cost reduction efforts, margins, growth, the financial success of the Company, the strength of its end markets, the outlook for the A&D, Test and USG segments, the ability to increase shareholder value, the timing and success of acquisition efforts, internal investments in new products and solutions, the impacts of inflation, the long-term success of the Company, and any other
statements which are not strictly historical are "forward-looking" statements within the meaning of the safe harbor provisions of the federal securities laws.
Investors are cautioned that such statements are only predictions and speak only as of the date of this presentation, and the Company undertakes no duty to update them except as may be required by applicable laws or regulations. The Company's actual results in the future may differ materially from those projected in the forward-looking statements due to risks and uncertainties that exist in the Company's operations and business environment including but not limited to those described in Item 1A, "Risk Factors", of the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2021; the availability and acceptance of viable COVID-19 vaccines by enough of the U.S. and world's population to curtail the pandemic; the continuing impact of the COVID-19 pandemic and the effects of known or unknown COVID-19
variants including labor shortages, facility closures, shelter in place policies or quarantines, material shortages, transportation delays, termination or delays of Company contracts, and the inability of our suppliers or customers to perform; the impacts of Executive Order 14042 and other vaccine mandates on our employees and businesses; the impacts of natural disasters on the Company's operations and those of the Company's customers and suppliers; the timing and content of future contract awards or customer orders; the appropriation, allocation and availability of Government funds; the termination for convenience of Government and other customer contracts or orders; weakening of economic conditions in served markets; the success of the Company's competitors; changes in customer demands or customer insolvencies; competition; intellectual property rights; technical difficulties; the success of the Company's acquisition efforts; delivery delays or defaults by customers; performance issues with key customers, suppliers and subcontractors; changes in the costs and availability of certain raw materials; labor disputes; changes in U.S. tax laws and regulations; other changes in laws and regulations including but not limited to changes in accounting standards and foreign taxation; changes in interest rates; costs relating to environmental matters arising from current or former facilities; uncertainty regarding the ultimate resolution of current disputes, claims, litigation or arbitration; and the integration of recently acquired businesses.
During this call, the Company may discuss some non-GAAP financial measures in describing the Company's operating results. A reconciliation of these measures to their most comparable GAAP measures can be found in the press release issued today and found on the Company's website at www.escotechnologies.comunder the link: Investor Relations.
In addition, the financial results presented in this presentation include certain non-GAAP financial measures such as EBIT, Adjusted EBIT, EBITDA, Adjusted EBITDA and Adjusted EPS. These non-GAAP financial measures are reconciled to their respective GAAP equivalents in the "Reconciliation of Non-GAAP Measures" presented below.
2
Q4 Results ($ in Millions, except per share amounts)
Entered Orders
258.5
244.7
Q4'21
Q4'22
Sales
256.5
205.5
Q4'21
Q4'22
Adjusted EBIT
42.8
28.2
16.7%
13.7%
Q4'21
Q4'22
Adjusted EPS
$1.21
$0.85
Q4'21
Q4'22
Entered Orders
Book-to-Billof 0.95 - record quarterly revenue > Q4 orders
Continuing strength in commercial aerospace & renewables
PY included acquired backlog at Altanova & Phenix
Sales
Sales increased 25% - Organic +19% and Acquisitions +6%
Organic Growth driven by commercial and defense aerospace, Navy, space, utility spending, renewables, medical/industrial shielding & power filters
Adjusted EBIT
Higher margins in A&D and Test, USG down slightly (23.7% vs 24.3%)
Q4'21
Q4'22
Delta $
Delta %
Entered Orders
$258.5
$244.7
($13.8)
-5.3%
Sales
205.5
256.5
51.0
24.8%
Adjusted EBIT
28.2
42.8
14.6
51.6%
Adj EBIT Margin
13.7%
16.7%
+3.0 pts
Adjusted EBITDA
40.0
54.9
14.9
37.1%
Adj EBITDA Margin
19.5%
21.4%
+1.9 pts
EPS GAAP
$0.78
$1.19
$0.41
52.6%
EPS Adjusted
$0.85
$1.21
$0.36
42.4%
3
A&D - Q4 ($ in Millions)
Entered Orders
88.6
97.5
Q4'21
Q4'22
Sales
103.7
80.1
Q4'21
Q4'22
Adjusted EBIT
23.6
22.7%
14.7
18.3%
Q4'21
Q4'22
Entered Orders
Q4'21
Q4'22
Delta $
Delta %
• Primarily driven by commercial aerospace recovery
Entered Orders
$88.6
97.5
8.9
10.0%
•
OEM production ramps & increased MRO
Sales
Sales
80.1
103.7
23.6
29.5%
•
Aerospace - Commercial +50% & Defense +22%
Adjusted EBIT
14.7
23.6
8.9
60.9%
• Navy +28% and Space +20%
Adj EBIT Margin
18.3%
22.7%
+4.4 pts
•
Partially offset by Industrial - VACCO
Adjusted EBIT
9/30/21
9/30/22
Delta $
Delta %
• Driven by leverage on higher volume & price increases, partially offset
Backlog
$367.2
408.3
41.1
11.2%
by wage and material cost inflation
• Strong recovery for PTI, Mayday & Westland
4
USG - Q4 ($ in Millions)
Entered Orders
96.0
87.8
Q4'21
Q4'22
Sales
83.5
61.1
Q4'21
Q4'22
Adjusted EBIT
19.8
14.9
23.7%
24.3%
Q4'21
Q4'22
Entered Orders
Decrease driven by timing of orders booked in Q4'21 related to acquired backlog - Altanova & Phenix
NRG +$7.2 (+76%) - Wind & Solar strength
Sales
Altanova & Phenix +$10.6M
Doble Organic +$10.2M (+22%) - increased electric utility spending
NRG +$1.6M (+16%) - strong demand across renewables product lines
Adjusted EBIT
Driven by leverage on higher revenue and price increases, partially offset by wage and material cost inflation, unfavorable mix & higher commissions
Q4'21
Q4'22
Delta $
Delta %
Entered Orders
$96.0
87.8
(8.2)
-8.6%
Sales
61.1
83.5
22.4
36.6%
Adjusted EBIT
14.9
19.8
4.9
33.2%
Adj EBIT Margin
24.3%
23.7%
-0.6 pts
9/30/21
9/30/22
Delta $
Delta %
Backlog
$91.6
128.2
36.6
39.9%
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Esco Technologies Inc. published this content on 17 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2022 21:28:02 UTC.
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
